l*******d
发帖数: 572 | 1 Derived from Strategic Transactions, Elsevier Business Intelligence’s
premium source for tracking life sciences deal activity, the Recent
Financings Of Private Companies column provides a comprehensive monthly
review of emerging life science companies that have received venture funding
, including companies within the In Vitro Diagnostics, Medical Devices, and
Pharmaceuticals sectors.
Recent Financings Of Private Companies, April 2013
Article preview from Start-Up - April, 2013
Singapore-based cancer diagnostics company Clearbridge BioMedics has raised
$S9mm ($7.2mm) through a Series B round led by Vertex Venture Holdings (the
VC arm of Temasek Holdings). New investors Spring Seeds Capital, Clearbridge
BSA Pte. Ltd, and Lu Yoh Chie (founder of Biosensors International) also
participated, along with returning backer BioVeda. Mr. Lu Yoh Chie becomes
Clearbridge’s chairman, and Vertex Venture takes a seat on the board. (Mar.)
Clearbridge was spun out of the National University of Singapore in 2009 to
develop a non-biomarker based system for the detection of circulating tumor
cells (CTCs) in the blood. The company’s first product is the ClearCell
system, which uses microfluidic biochips (CTChips) to isolate and retrieve
intact CTCs from small blood samples. The cells are then stained for
identification, counting, and further analysis to assist in the screening,
diagnosis, and staging of cancer, and also for personalized treatment
planning and post-therapy monitoring. Clearbridge will use the Series B
proceeds to develop a next-generation ClearCell system, which will consist
of the ClearCell unit and a single-use CTChip.
Diagnostics firm Saladax Biomedical Inc. received $22.4mm through the first
closing of its Series D round from new partner Shanghai Fosun Pharmaceutical
Group Co. Ltd. The company hopes to close the round at $30mm later this
year. Fosun's investment was made concurrent with an announcement that the
company will manufacture and market Saladax's MyCare chemotherapy dose
management assays in China. Saladax will use the Series D proceeds to expand
the MyCare line; it is currently marketed outside the US for use with three
widely known chemotherapies, and an additional ten assays are in
development. (Mar.)
Continued...
To read this article in its entirety, purchase now, as a PDF and
recieve it immediately via email. Or get it free when you subscribe to Start
-Up.
About Start-Up
No publication reviews leading edge companies and technology better than
Start-Up. Each issue of Start-Up profiles the most important new product
companies, identifies the hottest technology areas, reviews funds flowing
into private companies and investment trends, and reports on university tech
transfer licensing. Industries covered: pharmaceuticals, biotechnology,
medical equipment & devices, and in vitro diagnostics. |
|
